

Reproductive Genetics and the Obstetrics and Gynaecology Clinician

To the Editor:

The Genetics Committee of the SOGC strives consistently to keep members up to date with the clinical genetics aspects of obstetrics and gynaecology. The task is getting harder, because the level of genetic understanding required to provide genetic counselling continues to rise, there is a rapid technology/industry drive for non-invasive prenatal screening and diagnosis, and the commercial fight for test validation and subsequent market share continues.

How will the clinician be able to get informed consent from the patient if the genetic knowledge required to inform is currently beyond the medical school and residency curriculum?

Two documents highlight what are considered “core competencies in genetics” for health professionals¹ and medical school curricula.² These will be summarized to highlight this concern and the enlarging gap in genetics knowledge on the part of clinicians.

The National Coalition for Health Professional Education in Genetics recommends that, at a minimum, “each health care professional should be able to:

- a. examine one’s competence of practice on a regular basis, identifying areas of strength and areas where professional development related to genetics and genomics would be beneficial.
- b. understand that health-related genetic information can have important social and psychological implications for individuals and families.
- c. know how and when to make a referral to a genetics professional.”

The organization further includes learning points directed towards knowledge, skills, and attitudes.

The medical school curriculum in genetics recommended by the Association of Professors of Human and Medical Genetics in 2010 would require a significant increase in medical school teaching hours for genetics, and it is likely that these recommendations have not been initiated in

most Canadian medical schools. This curriculum change has not been implemented at the University of Calgary in its three year medical school curriculum. The following broad categories are recommended:

- a. Organization of the genome and regulation of gene expression as it relates to medical genetic diagnosis.
- b. Genetic variation and implications for diversity of normal variation and disease.
- c. Principles of inheritance patterns.
- d. Clinical, ethical, and social implications for diagnosis, family health, prediction, and personalized health.
- e. Importance of genetic testing including cytogenetics, molecular genetics, genome scanning, and biochemical genetics.
- f. Unique features of the genetics for cancer and prenatal diagnosis.
- g. Treatment of genetic conditions including family counselling.

The curriculum further includes learning points directed towards medical knowledge, patient care, interpersonal and communication skills, practice-based learning and improvement, professionalism, and system-based practice. From the broad categories above, the areas likely to be covered at present in Canadian medical schools are c, e, and f, but without the medical knowledge emphasis (in the student’s mind) that is placed on medical, surgical, and psychiatric topics.

This letter is intended to raise concern regarding the rapidly expanding genetics knowledge presently required in health care diagnosis, management, and treatment, and the real ability of medical students, residents, clinical fellows, and attending obstetrician-gynaecologists to acquire this new genetic knowledge. There are not enough reproductive geneticists (maternal fetal medicine subspecialists or medical geneticists) available to cover the clinical and counselling needs of patients and thereby allow them to provide truly “informed” consent.

R. Douglas Wilson,
MD, MSc, FRCSC, FACOG, FCCMG (Hon)
 Department of Obstetrics and Gynaecology,
 University of Calgary, Calgary AB

REFERENCES

1. Core Competencies in Genetics for Health Professionals. NCHQEG National Coalition for Health Professional Education in Genetics, Third edition. September 2007. Available at: <http://www.nchpeg.org/index>. Accessed July 11, 2012.
2. Medical School Core Curriculum in Genetics 2010. Association of Professors of Human and Medical Genetics. Available at: <http://www.aphmg.org/index.shtml>. Accessed July 11, 2012.

J Obstet Gynaecol Can 2012;34(11):1023–1024

A Review of Therapeutic Abortions and Related Areas of Concern in Canada

To the Editor:

Dr Sabourin and Dr Burnett present a cogent review¹ of the history and current status of induced (also called “therapeutic”²) abortion in Canada. I fully support their assessment of the many barriers women face in accessing abortion service in Canada and their call for better family planning education for the public and health professionals. Additionally, I thought some aspects of their review should be clarified or updated.

In their very appropriate discussion on contraception, Dr Sabourin and Dr Burnett discuss method effectiveness in terms of the “typical use” failure rates. Although this is not defined, they almost certainly refer to the “percentage of women experiencing an unintended pregnancy during the first year of typical use,”³ a definition of typical failure rate which I will use in this letter. They also indicate the proportion of Canadian women using certain contraceptive methods as a percentage. Thus, a reader may mistakenly assume that the percentages refer to the percentages of unintended pregnancies in the first year of use when noted in the sentence “[m]ethods with lower typical failure rates, such a male and female sterilization and intrauterine devices (13% and 4%, respectively) were used less frequently.”

Generally accepted typical-use failure rates are as follows:³

- intrauterine devices: 0.8% for copper-releasing devices and 0.2% for levonorgestrel-releasing devices in the first year;
- female sterilization: 0.5% in the first year; and
- male sterilization: 0.15% in the first year.

Further, JOGC readers may be interested to know that three emergency contraception pill (ECP) products are

currently approved and available in Canada.⁴ In addition to Plan B, mentioned by Dr Sabourin and Dr Burnett, consumers may also choose Next Choice (Cobalt Pharmaceuticals, Mississauga ON) or Norlevo (Laboratoire HRA Pharma, Paris, France), all containing the same dose of levonorgestrel for immediate use.

With respect to the discussion of the mechanism of action of the ECP, Dr Sabourin and Dr Burnett have clearly presented what was known at the time of their review in early 2011. However, more recent evidence supports a mechanism of ECP action that is solely a pre-ovulatory effect (i.e., it is no longer considered controversial to state that this method is not an abortifacient).^{5–7}

Finally I offer additional references to strengthen the authors’ discussion of the single case of maternal death due to *Clostridium sordellii* septic shock in a Canadian woman undergoing medical abortion.⁸ With a total of eight North American deaths due to *C. sordellii* following medical abortion since 2001, the accepted fatality rate is 0.58 per 100 000 women undergoing medical abortion.^{9–11} In 2006 the Planned Parenthood Federation of America revised their medical abortion protocol so that all misoprostol is delivered buccally rather than vaginally, and prophylactic antibiotics (doxycycline) are universally administered. It is unknown whether these changes have contributed to the absence of reported subsequent deaths among women who have received prophylactic antibiotics at the time of medical abortion. The clinical presentation of this infection can include abdominal pain, hypotension, and tachycardia, a high white cell count and hemoconcentration with accumulation of third space fluid. As this important and very rare infection can also occur in reproductive-age women regardless of pregnancy status,¹² and often without fever, a high index of suspicion for the infection in the presence of this symptom complex is in order.

I wish to thank Dr Sabourin and Dr Burnett again for their ambitious and timely review.

Wendy V. Norman, MD, MHSc
Faculty of Medicine, University of British Columbia,
Vancouver BC

REFERENCES

1. Sabourin JN, Burnett M. A review of therapeutic abortions and related areas of concern in Canada. J Obstet Gynaecol Can 2012;34(6):532–42.
2. Cessford TA, Norman WV. Making a case for abortion curriculum reform: a knowledge-assessment survey of undergraduate medical students [letter]. J Obstet Gynaecol Can 2011;33(10):993–4.
3. Trussell J. Contraceptive failure in the United States. Contraception 2011;83(5):397–404.

4. Health Canada. Drugs and health products: drug product database. Government of Canada. Available at: <http://hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php>. Accessed August 12, 2012.
5. International Federation of Gynecology and Obstetrics, International Consortium for Emergency Contraception. Statement on mechanism of action: how do levonorgestrel-only emergency contraceptive pills (LNG-ECPs) prevent pregnancy? FIGO-ICEC. March 2011. Available at: http://www.go.org/les/go-corp/MOA_FINAL_2011_ENG.pdf. Accessed April 4, 2011.
6. Prabakar I, Webb A. Emergency contraception. *BMJ* 2012;344:e1492. doi: 10.1136/bmj.e1492.
7. Cessford TA, Norman WV. Making a case for abortion curriculum reform: a knowledge-assessment survey of undergraduate medical students. *J Obstet Gynaecol Can* 2011;33(6):580.
8. Sinave C, Le Templier G, Blouin D, Leveillie F, Deland E. Toxic shock syndrome due to *Clostridium sordellii*: a dramatic postpartum and postabortion disease. *Clin Infect Dis* 2002;35:1441–3.
9. Meites E, Zane S, Gould C; for the *C. sordellii* Investigators. Fatal *Clostridium sordellii* infections after medical abortions. *N Engl J Med* 2010;363(14):1382–3.
10. Centers for Disease Control and Prevention (CDC). *Clostridium sordellii* toxic shock syndrome after medical abortion with mifepristone and intravaginal misoprostol—United States and Canada, 2001–2005. *MMWR Morb Mortal Wkly Rep* 2005;54(29):724.
11. Fischer M, Bhatnagar J, Guarner J, Reagan S, Hacker JK, Van Meter SH, et al. Fatal toxic shock syndrome associated with *Clostridium sordellii* after medical abortion. *N Engl J Med* 2005;353(22):2352–60.
12. Zane S, Guarner J. Gynecologic clostridial toxic shock in women of reproductive age. *Curr Infect Dis Rep* 2011;13(6):561–70.

In Response

To the Editor:

We greatly appreciate the findings emphasized by Dr Norman in response to our review highlighting areas of concern related to therapeutic abortions in Canada.¹

Dr Norman correctly states that the “typical failure rates” we reported for contraceptive methods represent the number of pregnancies per 100 women in the first year of use, as stated in the Canadian Contraception Consensus report.² This may also be referred to as the effectiveness of a method “as commonly used.”^{2,3} Additionally, we would like to thank her for clarifying that while sterilization and intrauterine devices are very effective methods of contraception (even as commonly used), they are only utilized by a minority of Canadians; that is, 13% report using sterilization and 4% report using an intrauterine device.²

We were pleased to learn that numerous levonorgestrel emergency contraception products are available in Canada

and that recent additional scientific literature dispels the myth that emergency contraception is an abortifacient. We hope this will facilitate access to emergency contraception for all women who stand to benefit from it.

Finally, we would like to thank Dr. Norman for providing additional references demonstrating the safety of therapeutic abortions and reminding readers of the potentially fatal signs and symptoms of *Clostridium sordellii* infections in women. It was brought to our attention that the case report we referenced in our review for a single death due to a *C. sordellii* infection after medical abortion in Canada has been retracted.⁴ The case was previously published by different authors in another journal.⁵ The retraction ensures that deaths attributed to sepsis following medical abortion is not over-counted.⁴

Although rare, fatal *C. sordellii* infections can occur after medically induced or surgical abortion or miscarriage or normal childbirth.⁶ Clinicians must be aware of the notable features of *C. sordellii* infection in this at-risk population. As a reminder, *C. sordellii* sepsis often presents without fever, but with hypotension, leukocytosis, hemoconcentration with third-space fluid accumulations and abdominal pain.⁶

Jeanelle N. Sabourin, MD, FRCSC

Department of Obstetrics and Gynecology, University of Alberta, Edmonton AB

Margaret Burnett, MD, FRCSC

Department of Obstetrics and Gynecology, University of Manitoba, Winnipeg MB

REFERENCES

1. Sabourin JN, Burnett M. A review of therapeutic abortions and related areas of concern in Canada. *J Obstet Gynaecol Can* 2012;34(6):532–42.
2. Black A, Francoeur D, Rowe T, Collins J, Miller D, Brown T, et al. Canadian contraception consensus. *J Obstet Gynaecol Can* 2004;26:143–56.
3. Hatcher RA. The essentials of contraceptive technology. Baltimore, MD: Population Information Program; 1997.
4. Notice of a second report of the same case. *Obstet Gynecol* 2005;105(3):673.
5. Sinave C, Le Templier G, Blouin D, Leveillie F, Deland E. Toxic shock syndrome due to *Clostridium sordellii*: a dramatic postpartum and postabortion disease. *Clin Infect Dis* 2002;35:1441–3.
6. Fischer M, Bhatnagar J, Guarner J, Reagan S, Hacker JK, Van Meter SH, et al. Fatal toxic shock syndrome associated with *Clostridium sordellii* after medical abortion. *N Engl J Med* 2005;353(22):2352–60.

J Obstet Gynaecol Can 2012;34(11):1024–1025